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Abstract 
Background: Lifestyle factors including obesity and smoking are suggested to be correlated with increased risk of 
COVID-19 severe illness or related death. However, whether these relationships are causal is not well known; neither 
for the relationships between COVID-19 severe illness and other common lifestyle factors, such as physical activity 
and alcohol consumption.
Methods: Genome-wide significant genetic variants associated with body mass index (BMI), lifetime smoking, 
physical activity and alcohol consumption identified by large-scale genome-wide association studies (GWAS) of up 
to 941,280 individuals were selected as instrumental variables. Summary statistics of the genetic variants on severe 
illness of COVID-19 were obtained from GWAS analyses of up to 6492 cases and 1,012,809 controls. Two-sample Men-
delian randomisation analyses were conducted.
Results: Both per-standard deviation (SD) increase in genetically predicted BMI and lifetime smoking were associ-
ated with about two-fold increased risks of severe respiratory COVID-19 and COVID-19 hospitalization (all P < 0.05). 
Per-SD increase in genetically predicted physical activity was associated with decreased risks of severe respiratory 
COVID-19 (odds ratio  [OR] = 0.19; 95% confidence interval  [CI], 0.05, 0.74; P = 0.02), but not with COVID-19 hospitali-
zation (OR = 0.44; 95% CI 0.18, 1.07; P = 0.07). No evidence of association was found for genetically predicted alcohol 
consumption. Similar results were found across robust Mendelian randomisation methods.
Conclusions: Evidence is found that BMI and smoking causally increase and physical activity might causally decrease 
the risk of COVID-19 severe illness. This study highlights the importance of maintaining a healthy lifestyle in protecting 
from COVID-19 severe illness and its public health value in fighting against COVID-19 pandemic.
Keywords: COVID-19, Lifestyle factors, Mendelian randomisation, Causation assessment, Obesity, Smoking, Alcohol 
consumption, Physical activity
© The Author(s) 2021. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which 
permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the 
original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or 
other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line 
to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory 
regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this 
licence, visit http://creat iveco mmons .org/licen ses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creat iveco 
mmons .org/publi cdoma in/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
Background
Obesity and smoking are well-known health-related 
lifestyle factors. Studies have reported the correla-
tions between obesity and severe illness or related 
death of COVID-19 [1–3]. For smoking, its relation-
ship with the risk of severe COVID-19 is controversial: 
some studies suggest that current smokers might have 
a lower risk [2, 4–6]. However, the Centre for Disease 
Control and Prevention suggests that both people with 
obesity and smoking are at increased risk of COVID-
19 severe illness [7]. The relationships mentioned above 
are mainly suggested by observational studies, which 
of themselves are subject to bias, provide low level of 
evidence and have limited ability in supporting causal-
ity. For other lifestyle factors, such as physical activ-
ity and alcohol consumption, little is known about if 
they are associated with severe illness of COVID-19. A 
study has found that accelerometer-measured physical 
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activity was associated with decreased likelihood of 
being a COVID-19 patient in the UK Biobank; no asso-
ciation was found for accelerometer-measured physical 
activity with the likelihood of death related to COVID-
19, or for self-reported physical activity with the likeli-
hoods of being a COVID-19 patient or of death related 
to COVID-19 [8].
Mendelian randomisation (MR) uses exposure-asso-
ciated genetic variants as instrumental variables to 
assess the causality between exposures and outcomes 
[9]. As genetic variants are randomly allocated at con-
ception, MR resembles a randomised controlled trial 
and is less subject to confounding than observational 
studies. The publicly available genome-wide association 
studies (GWAS) summary statistics provide valuable 
resources for assessing the causality between lifestyle 
factors and the risk of COVID-19 severe illness.
MR studies have been conducted to investigate the 
causality of body mass index (BMI), smoking and physi-
cal activity with COVID-19 risk. Inconsistent results 
have been found for BMI [8, 10, 11], a causal effect with 
limited precision has been found for smoking [10], and 
no evidence of causality was found for physical activ-
ity [8]. However, the sample sizes of these studies could 
have limited the abilities of these studies in detecting 
causal evidence and obtaining precise causal effect 
estimates.
This study aimed to investigate the causality between 
four lifestyle factors, namely BMI, smoking, physical 
activity and alcohol consumption, and severe illness of 




Summary-level data were obtained from two GWAS 
analyses conducted by the COVID-19 Host Genetic Ini-
tiative [13] (Release 4 in September 2020): (1) 2972 very 
severe respiratory confirmed COVID-19 cases, which 
were defined as hospitalized laboratory confirmed SARS-
CoV-2 infection (RNA and/or serology based) with 
death or respiratory support, and hospitalization with 
COVID-19 as primary reason for admission, compared 
with 284,472 population controls; and (2) 6492 hospital-
ized confirmed COVID-19 cases, which were defined as 
hospitalized laboratory confirmed SARS-CoV-2 infection 
(RNA and/or serology based) and hospitalization due to 
corona-related symptoms, compared with 1,012,809 con-
trols. The majority (≥ 90%) of the participants included 
in the GWAS analyses were of European ancestry. Details 
of the GWAS analyses can be found at https ://www.covid 
19hg.org/.
Genetic instrumental variables to lifestyle factors
Genome-wide significant genetic variants identified from 
GWAS were selected as instrumental variables for the 
investigated lifestyle factors. This study only used inde-
pendent sentinel genetic variants found from primary 
analysis of relevant GWAS; genetic variants identified 
from conditional analysis, i.e., secondary signals, were 
not used.
• BMI: 656 variants with P < 10–8 (Additional file  1: 
Supplementary Table  1) identified from the meta-
analysis of up to 681,275 individuals of European 
ancestry from the Genetic Investigation of ANthro-
pometric Traits consortium and UK Biobank, 
explaining ~ 7.0% variation in BMI [14].
• Smoking: 126 variants with P < 5 × 10–8 (Additional 
file  1: Supplementary Table  2) identified from the 
GWAS of up to 462,690 individuals from the UK 
Biobank for a lifetime smoking measure capturing 
smoking initiation, heaviness and duration, explain-
ing 1.3% variation in the lifetime smoking measure 
[15].
• Physical activity: five variants with P < 5 × 10–8 (Addi-
tional file  1: Supplementary Table  3) identified to 
be associated with accelerometer-measured overall 
physical activity (measured as average vector magni-
tude) in a sample of up to 91,105 UK Biobank indi-
viduals, explaining ~ 0.2% variation in overall physical 
activity [16].
• Alcohol consumption: 81 variants with P < 5 × 10–8 
(Additional file  1: Supplementary Table  4) identi-
fied to be associated with standard drinks per week 
in a sample of up to 941,280 individuals of European 
ancestry from the GWAS and Sequencing Consor-
tium of Alcohol and Nicotine use, explaining ~ 0.6% 
variation in alcohol consumption measured as drinks 
per week [17].
Proxies with a minimum linkage disequilibrium  r2 = 0.8 
were used for two (Additional file  1: Supplementary 
Table 1), two (Additional file 1: Supplementary Table 3) 
and one (Additional file 1: Supplementary Table 4) vari-
ants of BMI, physical activity and alcohol consumption, 
respectively, that were unavailable in the COVID-19 data 
sources. One alcohol consumption variant had no proxy 
available, so it was not included in analysis.
Statistical analyses
The statistical power was calculated using the proportion 
of variation in the lifestyle factor explained by the genetic 
instrumental variables, the sample sizes of the COVID-
19 GWAS, and the method proposed by Burgess [18]. 
From the formula (12) of Burgess, the causal effect size 
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β, log-OR per-standard deviation (SD) increase in the 
genetically predicted lifestyle factor, can be detected with 
80% statistical power at the significance level of 0.05 is
where  Φ−1 is the inverse of the cumulative distribu-
tion function of the standard normal distribution, ρGX2 
is the proportion of variation in the lifestyle risk fac-
tor explained by the genetic instrumental variables, N is 
the sample size of the COVID-19 GWAS, and ℙ(Y = 1) 
and ℙ(Y = 0) are the proportions of cases and controls, 
respectively, in the COVID-19 GWAS. The values of the 
parameters used in the calculation for each lifestyle factor 
can be found in Additional file 2: Supplementary Table 5.
The main analyses were performed using inverse-var-
iance weighted (IVW) method under a random-effects 
model [19], which assumes that all genetic variants are 
valid instrumental variables, or any horizontal pleiotropy, 
i.e., genetic variants were associated with COVID-19 
risk through pathways other than the investigated life-
style factor, must be balanced. The reported odds ratios 
(ORs) on COVID-19 risk were for per-SD increase in 
the genetically predicted value in BMI, lifetime smoking 
measure, accelerometer-measured physical activity and 
alcohol consumption (log-transformed standard drinks 
per week).
Leave-one-out analyses, i.e., applying IVW after 
removing each genetic variant in turn, were performed 
to assess if the results were driven by any single variant. 
If there were any, relevant genetic variants were removed 
and ORs were estimated again.
Sensitivity analyses were performed using MR-Egger 
regression [20], weighted median method [21] and 
weighted mode method [22], which relax MR assump-
tions and allow some genetic instrumental variables to 
be invalid, but are less powerful than IVW method. MR-





NP(Y = 1)P(Y = 0)
estimates even all genetic instrumental variables are inva-
lid, while weighted median and weighted mode methods 
can provide consistent causal effect estimates when up to 
50% genetic instrumental variables are invalid. The more 
consistency across the point estimates of the methods, 
the greater the evidence supporting the causal effect of 
the investigated lifestyle factor on COVID-19 severe ill-
ness. The overall directional pleiotropy of the genetic 
instrumental variables, i.e., unbalanced horizontal pleiot-
ropy, can be detected by the intercept of the MR-Egger 
regression, which is expected to be different from zero if 
directional pleiotropy exists.
The analyses were conducted using the TwoSampleMR 
R package [23]. All statistical tests were two-sided. 
Results with a nominal P value < 0.05 were considered 
statistically significant.
Results
For BMI, lifetime smoking, physical activity and alcohol 
consumption, respectively, this study has 80% statistical 
power at the significance level of 0.05 to detect a per-SD 
OR of 1.22, 1.57, 3.23 and 1.96 or greater on severe res-
piratory COVID-19, and an per-SD OR of 1.14, 1.36, 2.21 
and 1.58 or greater on COVID-19 hospitalization.
Table  1 shows the causal effect estimates using IVW 
method. Both genetically predicted BMI and lifetime 
smoking were found to be associated with increased risk 
of COVID-19 severe illness: the per-SD OR of geneti-
cally predicted BMI was 1.91 (95% confidence interval 
[CI], 1.55, 2.35, P = 7.4 × 10–10) for severe respiratory 
COVID-19 and 1.75 (95% CI 1.52, 2.01; P = 9.0 × 10–10) 
for COVID-19 hospitalization; the per-SD OR of geneti-
cally predicted lifetime smoking was 1.84 (95% CI, 1.08 
to 3.13, P = 0.02) for severe respiratory COVID-19 and 
2.15 (95% CI 1.52, 3.03; P = 1.5 × 10–5) for COVID-19 
hospitalization. Genetically predicted physical activity 
was found to be associated with decreased risk of severe 
respiratory COVID-19 (per-SD OR = 0.19; 95% CI 0.05, 
Table 1 Odds ratios (OR) and 95% confidence intervals (CI) of  the genetically predicted lifestyle factors with COVID-19 
severe illness
OR and 95% CI were expressed as per standard deviation increase in genetically predicted levels in body mass index, lifetime smoking, accelerometer-measured 
physical activity and alcohol consumption (log-transformed standard drinks per week)
Lifestyle factor Number 
of variants
Severe respiratory COVID‑19 COVID‑19 hospitalization
OR (95% CI) P OR (95% CI) P
Body mass index 656 1.91 (1.55, 2.35) 7.4 × 10–10 1.75 (1.52, 2.01) 9.0 × 10–15
Lifetime smoking 126 1.84 (1.08, 3.13) 0.02 2.15 (1.52, 3.03) 1.5 × 10–05
Physical activity 5 0.19 (0.05, 0.74) 0.02 0.44 (0.18, 1.07) 0.07
Alcohol consumption: all variants 80 1.64 (0.70, 3.81) 0.25 1.57 (0.90, 2.73) 0.11
Alcohol consumption: rs1229984, 
rs2532276 removed
78 0.64 (0.25, 1.64) 0.35 1.11 (0.57, 2.17) 0.76
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0.74; P = 0.02), but not with COVID-19 hospitalization 
(per-SD OR = 0.44; 95% CI 0.18, 1.07; P = 0.07), though 
most of the 95% CI did not include one. No evidence of 
association was found for genetically predicted alco-
hol consumption with severe respiratory COVID-19 
or COVID-19 hospitalization (both P > 0.1). There was 
evidence of heterogeneity between the genetic variants 
of BMI and alcohol consumption, respectively, but not 
between those of lifetime smoking or physical activity 
(Table 2).
From the leave-one-out analyses, similar OR estimates 
were found for BMI (Additional files 4, 5: Supplemen-
tary Figs. 1 and 2), lifetime smoking (Additional files 6, 7: 
Supplementary Figs. 3 and 4) and physical activity (Addi-
tional files 8, 9: Supplementary Figs. 5 and 6), suggesting 
that the observed associations for these three geneti-
cally predicted lifestyle factors were unlikely to be driven 
by any single genetic variant outlier. Genetic variants 
rs1229984 and rs2532276 appeared to be substantially 
influence the OR estimates in the analyses for alcohol 
consumption with both severe respiratory COVID-19 
(Additional file 10: Supplementary Fig. 7) and COVID-19 
hospitalization (Additional file 11: Supplementary Fig. 8). 
After removing the two variants, genetically predicted 
alcohol consumption had a per-SD OR = 0.64 (95% CI 
0.25, 1.64; P = 0.35) with severe respiratory COVID-19, 
and a per-SD OR = 1.11 (95% CI 0.57, 2.17; P = 0.76) with 
COVID-19 hospitalization (Table 1). Although weak evi-
dence of heterogeneity between the remaining genetic 
variants were still found (Table  2), the leave-one-out 
analyses did not suggest there were significant outliers 
left (Additional files 12, 13: Supplementary Figs.  9 and 
10). The two variants were removed from subsequent 
analyses.
Although there was evidence of heterogeneity between 
the genetic variants of BMI (Table  2), the tests of MR-
Egger regression intercepts suggested there was no evi-
dence of overall directional pleiotropy of the genetic 
variants on COVID-19 hospitalization (P = 0.21), and 
a weak evidence in the analysis for severe respiratory 
COVID-19 (Intercept = 0.009; 95% CI 0.001, 0.018; 
P = 0.02; Table  3). These were also supported by the 
MR funnel plots, which was generally symmetrical for 
COVID-19 hospitalization and little asymmetrical for 
severe respiratory COVID-19 (Additional files 14, 15: 
Supplementary Figs.  11 and 12). No evidence of overall 
directional pleiotropy was found for the genetic variants 
of the other three lifestyle factors (all P > 0.18). The MR 
funnel plots for lifetime smoking (Additionals file 16, 17: 
Supplementary Figs. 13 and 14) and alcohol consumption 
(Additional files 18, 19: Supplementary Figs.  15 and 16) 
were generally symmetrical, while the plots for physical 
Table 2 Heterogeneity test results for the genetic variants
Lifestyle factor Method Q df P
Severe respiratory COVID-19
Body mass index Inverse variance weighted 776.073 655 7.4 × 10–04
Body mass index MR-Egger 770.065 654 1.1 × 10–03
Lifetime smoking Inverse variance weighted 137.387 125 0.21
Lifetime smoking MR-Egger 137.335 124 0.19
Physical activity Inverse variance weighted 3.273 4 0.51
Physical activity MR-Egger 3.005 3 0.39
Alcohol consumption: all variants Inverse variance weighted 118.041 79 2.9 × 10–03
Alcohol consumption: all variants MR-Egger 110.051 78 0.01
Alcohol consumption: rs1229984, rs2532276 removed Inverse variance weighted 99.353 77 0.04
Alcohol consumption: rs1229984, rs2532276 removed MR-Egger 99.280 76 0.04
COVID-19 hospitalization
Body mass index Inverse variance weighted 772.906 655 9.7 × 10–04
Body mass index MR-Egger 771.083 654 1.0 × 10–03
Lifetime smoking Inverse variance weighted 131.212 125 0.33
Lifetime smoking MR-Egger 131.192 124 0.31
Physical activity Inverse variance weighted 3.629 4 0.46
Physical activity MR-Egger 1.852 3 0.60
Alcohol consumption: all variants Inverse variance weighted 117.782 79 3.1 × 10–03
Alcohol consumption: all variants MR-Egger 115.557 78 3.7 × 10–03
Alcohol consumption: rs1229984, rs2532276 removed Inverse variance weighted 108.280 77 0.01
Alcohol consumption: rs1229984, rs2532276 removed MR-Egger 108.188 76 0.01
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activity could not properly be assessed as there were five 
genetic variants only (Additional files 20, 21: Supple-
mentary Figs.  17 and 18). From the sensitivity analyses, 
causal effect estimates with  consistent directions were 
found across the MR-Egger regression, weighted median 
method and weighted mode method for all the investi-
gated lifestyle factors, though some estimates were with 
wider 95% CIs (Fig. 1).
Discussion
Using a two-sample MR approach, we found evi-
dence that BMI has a causal effect on increased risk of 
COVID-19 severe illness, same as the findings by Pons-
ford et al. [10] and Leong et al. [11], but different from 
those by Zhang et  al. [8]. Our causal effect estimates 
were of greater precision, in terms of the width of the 
confidence interval (log-OR scale), than those found by 
Ponsford et al., e.g., the per-SD OR on COVID-19 hos-
pitalization estimated by Ponsford et al. was 1.47 (95% 
CI 1.18, 1.83) with a confidence interval width of 0.44, 
while we estimated it to be 1.75 (95% CI 1.52, 2.01) 
with a confidence interval width of 0.28. The difference 
is likely to be due to that we used the summary statis-
tics from COVID-19 GWAS analyses of larger sample 
sizes; Ponsford et al. used the summary statistics from 
a GWAS of severe COVID-19 with respiratory failure 
including 1610 cases and 2205 controls [24], and the 
Release 3 data from the COVID-19 Host Genetic Ini-
tiative including 3199 cases and 897,488 controls in 
the GWAS of COVID-19 hospitalization. Leong et  al. 
[11] also used the Release 3 data from the COVID-19 
Host Genetic Initiative but reported the OR as per 
unit increase in BMI, e.g., 1.12 (95% CI 1.03, 1.13) for 
COVID-19 hospitalization; therefore, their results can-
not be directly compared with ours. The MR study by 
Zhang et  al. [8] reported null associations between 
genetically predicted BMI and COVID-19 outcomes 
including being a COVID-19 patient and death related 
to COVID-19, different from the outcomes investigated 
in our study. Zhang et al. used the UK Biobank data, the 
sample size of which might not provide sufficient statis-
tical power to detect an association.
Fig. 1 Odds ratios (OR) and 95% confidence intervals (CI) of the genetically predicted lifestyle factors with COVID-19 severe illness across Mendelian 
randomisation methods. OR and 95% CI were expressed as per standard deviation increase in genetically predicted levels in body mass index (BMI), 
lifetime smoking measure, accelerometer-measured physical activity and alcohol consumption (log-transformed standard drinks per week). The 
plots were right-truncated to better present the confidence intervals
Table 3 Test results for the MR-Egger regression intercepts






Body mass index 0.010 0.004 0.02
Lifetime smoking 0.003 0.016 0.83






Body mass index 0.004 0.003 0.21
Lifetime smoking 0.001 0.010 0.89
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The finding for BMI is consistent with the correlation 
between obesity and severe illness observed in COVID-
19 patients [1–3]. Obesity is plausible to contribute 
to COVID-19 severe illness. Featured with increased 
macrophage infiltration that associated with abnormal 
production of pro-inflammatory cytokines and insulin 
secretory, obesity contributes to systemic immune dys-
regulation [25–27], which could contribute to abnormal 
immune response to the coronavirus SARS-CoV-2 that 
results severe illness [28].
We found evidence that lifetime smoking has a causal 
effect on increased risk of COVID-19 severe illness, same 
as the findings by Ponsford et al. investigating the same 
lifetime smoking measure [10]. Similar to the results for 
BMI, our causal effect estimates for lifetime smoking 
were of greater precision than those found by Ponsford 
et al. For comparison, the per-SD OR on COVID-19 hos-
pitalization estimated by Ponsford et  al. was 4.27 (95% 
CI 2.10, 8.65) with a confidence interval width of 1.42, 
while we estimated it to be 2.15 (95%: 1.52, 3.03) with a 
confidence interval width of 0.69. In COVID-19 patients, 
smoking has not been found to be associated with the 
risk of death [2], and lower than expected prevalence of 
smoking has even been observed [4–6]. However, these 
studies considered smoking as a binary (current, non-
current smokers) or categorical (current, former, never 
smokers) variable only without any consideration on 
smoking heaviness or duration. In addition, there might 
be misclassification in the collected smoking behaviours 
for COVID-19 patients, especially in emergency contexts. 
The lifetime smoking measure used by our study is more 
accurate to reflect the cumulative exposure to smoking, 
and it has been validated to be associated with lung can-
cer and coronary heart disease through MR analyses [15].
For the first time, we provided evidence that physi-
cal activity causally decreases the risk of severe respira-
tory COVID-19. Physical activity studied in this study 
is measured by accelerometer [16]; therefore, it is more 
accurate than self-reported one. The MR study by Zhang 
et al. [8] using UK Biobank data reported a null associa-
tion for either accelerometer-measured or self-reported 
physical activity; however, similar to their analyses for 
BMI, they studied different COVID-19 outcomes and 
the sample size might not be sufficient. Nevertheless, 
only five genetic instrumental variables were used by our 
study, and they explained ~ 0.2% variation in accelerome-
ter-measured physical activity only; the estimates for the 
causal effects were not of great precision. Furthermore, 
although the MR-Egger regression intercept was not dif-
ferent from zero, it had a considerable magnitude with 
a suggestion that there might be horizontal pleiotropy 
of the physical activity genetic instrumental variables. 
The association could be driven by BMI, as there was a 
negative genetic correlation between physical activity 
and BMI [16].
For alcohol consumption, although we found evidence 
that there were two outlier genetic variants influencing 
the association estimates using all genetic variants and 
removed the two variants, null associations were found. 
The null associations suggest that alcohol consumption 
might not change the risk of COVID-19 severe illness. 
However, the null associations might also be due to sta-
tistical power; our study did not have sufficient power to 
detect small effect sizes as the observed ORs of 1.64 and 
1.11 with severe respiratory COVID-19 and COVID-19 
hospitalization, respectively.
BMI, smoking and physical activity are modifiable, so 
they could be targeted to reduce severe illness of COVID-
19. This study highlights the importance of maintaining 
a healthy lifestyle in protecting from COVID-19 severe 
illness. The findings also have a profound public health 
value—a healthy lifestyle could be helpful for fighting 
against the COVID-19 pandemic.
Limitations of this study included that there might 
be bias in the causal effect estimates, as there was some 
sample overlapping between the lifestyle factors GWAS 
and COVID-19 GWAS, e.g., UK biobank participants 
were included in the GWAS of COVID-19 hospitali-
zation. However, the bias might not be substantial, 
because UK Biobank contributed 413 cases (6.4% of the 
total cases) only to and 99.9% UK Biobank participants 
were controls in the GWAS of COVID-19 hospitaliza-
tion (no UK Biobank participants were included in the 
GWAS of severe respiratory COVID-19; see Additional 
file  3: Supplementary Table  6), with an implication that 
the vast majority of the overlapping samples were likely 
to be controls in the GWAS of COVID-19; an unbiased 
causal effect estimate is expected if the associations 
between risk factor and genetic instrumental variables 
are obtained from controls [29]. Another limitation is 
that the findings might not be applicable to populations 
of non-European ancestry, as the exposure and outcome 
summary statistics for the genetic instrumental vari-
ables were from GWAS of participants almost entirely 
of European ancestry. Our main analysis included eight 
statistical tests, but we did not perform multiple testing 
adjustment; however, the five associations for BMI, life-
time smoking and physical activity with nominal P < 0.05 
were still significant even assessed using the false discov-
ery rate (FDR; all FDR < 0.04).
Conclusions
This two-sample MR study finds evidence that BMI and 
smoking causally increase and physical activity might 
causally decrease the risk of COVID-19 severe illness, 
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with an implication that maintaining a healthy lifestyle 
could protect from severe illness of COVID-19.
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